Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2018-01-11 Regulatory Filings
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Klarläggande avseende Rorgamma projektet
Regulatory Filings Classification · 95% confidence The document is very short (482 characters) and appears to be a clarification or statement regarding a specific project ('RORgamma projektet') issued by Karo Pharma on January 11, 2018. It addresses misinformation and confirms the project is proceeding as planned. It does not contain detailed financial statements (ruling out 10-K, IR, ER), management changes (MANG), or voting results (DVA). Given its nature as a specific, non-standard announcement clarifying a business situation, and its brevity, it fits best under the general regulatory announcement category, 'Regulatory Filings' (RNS), as it doesn't align with the more specific categories like DIV, CAP, or LTR.
2018-01-11 Swedish
KARO PHARMAS FÖRETRÄDESEMISSION KRAFTIGT ÖVERTECKNAD
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated January 4, 2018, detailing the results of a rights issue ('förtädesemission') for Karo Pharma, which was heavily oversubscribed. It discusses the amount raised (approx. 794.3 Mkr), the allocation of shares, and the resulting changes in share capital and the number of shares. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is a formal announcement, the core subject matter is the financing event itself, not just the announcement of a report (RPA) or a general regulatory filing (RNS).
2018-01-04 Swedish
KARO PHARMA OFFENTLIGGÖR PROSPEKT
Capital/Financing Update Classification · 95% confidence The document is titled "KARO PHARMA OFFENTLIGGÖR PROSPEKT" (Karo Pharma Publishes Prospectus) and explicitly states that the prospectus regarding a rights issue has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). It also mentions that the invitation to subscribe for shares will only occur through the prospectus. This document itself is a press release announcing the publication of a formal offering document (the prospectus). Since the core action is the announcement of a capital-raising document (prospectus), and the text is short (4261 chars) and serves to inform the public about the availability of the prospectus and related regulatory requirements (like LEI/NID for MiFID II compliance), it fits best under Capital/Financing Update (CAP) or potentially Report Publication Announcement (RPA) if it were just announcing a standard report. However, because it details a specific financing activity (rights issue) and the associated regulatory steps for participation, 'CAP' is the most precise fit for the underlying event. If the document *was* the prospectus, it would be CAP, but as an announcement of the prospectus for a financing event, CAP is appropriate, though RPA is a close secondary consideration based on the 'announcement' nature.
2017-12-12 Swedish
BESLUT VID KARO PHARMAS EXTRA BOLAGSSTÄMMA DEN 8 DECEMBER 2017
AGM Information Classification · 99% confidence The document is titled "BESLUT VID KARO PHARMAS EXTRA BOLAGSSTÄMMA DEN 8 DECEMBER 2017" (Decisions at Karo Pharma's Extraordinary General Meeting on December 8, 2017). The content details resolutions passed at this meeting, specifically concerning a rights issue (nyemission) involving the issuance of new shares and changes to the company's articles of association regarding share capital limits. This directly relates to capital structure changes and share issuance. While it originates from a General Meeting (suggesting AGM-R or DVA), the core subject is the capital increase/share issuance. The most specific category covering the issuance of new shares and capital structure changes is 'Share Issue/Capital Change' (SHA). Since the document details the mechanics of the share issuance (rights ratio, subscription period, price), SHA is the best fit over a general AGM result (AGM-R) or a general capital announcement (CAP).
2017-12-08 Swedish
VILLKOREN FÖR KARO PHARMAS FULLT SÄKERSTÄLLDA FÖRETRÄDESEMISSION FASTSTÄLLDA
Capital/Financing Update Classification · 98% confidence The document text is a formal announcement from Karo Pharma AB dated December 5, 2017, detailing the finalized terms ('fastställt villkoren') for a rights issue ('företrädesemission'). It specifies the subscription price (29.00 SEK), the maximum capital to be raised (794.3 MSEK), the subscription period, and includes a preliminary timeline. Crucially, the final section states: 'Inbjudan till berörda personer att teckna aktier i Karo Pharma kommer endast att ske genom det prospekt som Karo Pharma beräknar offentliggöra omkring den 12 december 2017.' This indicates the document itself is an announcement setting the stage for a future offering document (the prospectus). Since the content is focused on a financing activity (rights issue/share issue) and is a formal press release announcing the terms, it aligns best with the Capital/Financing Update (CAP) category. It is not the full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate financing event.
2017-12-05 Swedish
ANGÅENDE FÖRSÄLJNINGEN AV AKTIERNA I OASMIA AB
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated November 30, 2017, titled 'REGARDING THE SALE OF SHARES IN OASMIA AB'. It addresses a specific legal/regulatory matter: a director (Anders Lönner) being called for questioning regarding suspected insider trading related to a share sale, and the board's conclusion that the company acted correctly. The text explicitly states that the information is required to be made public under the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This content strongly suggests a disclosure related to potential market misconduct or legal scrutiny, which fits best under 'Legal Proceedings Report' (LTR) or potentially a general 'Regulatory Filing' (RNS). Given the focus on insider trading allegations and the subsequent investigation/statement, LTR is the most specific fit, as it deals with significant legal/regulatory matters involving the company and its executives. It is not an earnings release, a director's dealing report (which reports actual trades), or a general announcement of a report.
2017-11-30 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.